Cellectis S.A. (CLLS) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Cellectis S.A.
Address
8, rue de la Croix Jarry
Paris, IF 75013
France
Phone
33 1 81 69 16 00
Website
Sector
Healthcare
Industry
Biotechnology
Employees
229
First IPO Date
March 24, 2015
Key Executives
| Name | Title | Pay | Year Born |
| David J. Sourdive | Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Director | 636,274 | 1967 |
| Andre Choulika | Co-Founder, Chief Executive Officer & Director | 982,873 | 1965 |
| Marie-Bleuenn Terrier | General Counsel & Secretary of the Board of Directors | 0 | 1982 |
| Pascalyne Wilson | Director of Communications | 0 | N/A |
| Stephan Reynier | Chief Regulatory & Pharmaceutical Compliance Officer | 0 | 1969 |
| Kyung Nam-Wortman | Executive Vice President & Chief Human Resources Officer | 0 | 1970 |
| Jean Charles Epinat | Chief Technological Officer | 0 | N/A |
| Valerie Cros | Principal Financial Officer & Principal Accounting Officer | 0 | N/A |
| Philippe Duchateau | Chief Scientific Officer | 0 | 1963 |
| Arthur Stril | Chief Financial Officer & Chief Business Officer | 0 | 1989 |
Description
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
